Skip to main content
. 2018 Apr 20;9(30):21444–21458. doi: 10.18632/oncotarget.25118

Figure 1. MAP3K1 inhibition reduces sensitivity to upstream PI3K pathway inhibitors.

Figure 1

(A) MCF7, T47D and MCF10A-PI3KαH1047R cells were cultured and transfected with MAP3K1 (siM3K1P) or control (scRNA) siRNAs for 48h. Cultures were treated with 250nM AZD8835 (+) or DMSO (−) as indicated 24h prior to cell lysis. Cell lysates were then immunoblotted with indicated antibodies (Abs). P-values were determined by the Student's t-test. (B) Lysates from MCF7 parental and MAP3K1-deficient (CR1.4 and CR2.5) cells were cultured and treated with 250 nM AZD8835 or 25 nM AZD5363 as indicated. Lysates were collected and processed for immunoblotting with the indicated Abs. (C) IncuCyte cell proliferation assays showing relative % of confluence of MCF7 parental versus MAP3K1-deficient (CR1.4 and CR2.5) cultures treated with DMSO (black), AZD8835 (red) and AZD5363 (green) for 66 hours. * Statistical significance of p < 0.05, determined by the Student's t-test.